MedTrace Logo

Efficacy and Safety of Sirolimus in COVID-19 Infection

NCT04461340 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-09-09

No results posted yet for this study

Summary

This research is planned to illustrate the efficacy and safety of sirolimus as an adjuvant agent to the standard treatment protocol against COVID-19 infection

Conditions

  • COVID 19

Interventions

DRUG

Sirolimus

oral dose of 6 mg on day1 followed by 2 mg daily for 9 days

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Mohamed Mamdouh Elsayed, MD · lecturer

  • Ayman I Baess, MD · Associate professor

  • Heba M El weshahi, MD · professor

  • Nermine H Zakaria, MD · professor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-15
Primary Completion
2020-10-30
Completion
2020-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04461340 on ClinicalTrials.gov